BioSpace News Archive

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced that it plans to release unaudited financial results for the second quarter and first half of fiscal year 2020 on Tuesday, November 26, 2019, after the market close.

iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, announced today that its Vice President, Antibody Development, Stefanie Urlinger, PhD, delivered a podium presentation highlighting the discovery of IGSF11

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCyte’s Flow Electroporation® technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic

Aruna Bio, Inc. announced that Dr. Mark Sirgo, Chief Executive Officer, and Dr. Steve Stice, Chief Scientific Officer, will be presenting at the 31st Annual Piper Jaffray Healthcare Conference in New York City on Thursday, December 5th at a new time of 9:30 AM Eastern Time.

Biogen Inc. announced the enrollment of the last patient in the global Phase 3 STAR clinical study, which is evaluating the investigational gene therapy timrepigene emparvovec for the treatment of choroideremia.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next-generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it expanded its research collaboration with the Karolinska Institutet in Stockholm, Sweden.

Immunexpress, Inc. today announced the U.S. Patent and Trademark Office (USPTO) has granted Patent No. U.S. 10,364,474 B2, which covers single nucleotide polymorphisms (SNPs) in the ribosomal DNA of bacteria and fungi.

Phase 1 Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients

Tonix Pharmaceuticals Holding Corp. announced that, having successfully closed an underwritten public equity offering for $9.0 million, it has initiated the Phase 3 RELIEF study.